AttributesValues
rdf:type
Description
  • V této randomizované studii III skupiny EORTC Leukemia Cooperative Group je analyzováno léčení pacientů s MDS s poruchou krvetvorby v 10-30%. (cs)
  • In this randomized phase III study of the EORTC Leukemia Cooperative Group, treatemet of patients with myelodysplastic syndromes (MDS) with 10-30% bone marrow blasts and hematopoietic failure is analyzed.
  • In this randomized phase III study of the EORTC Leukemia Cooperative Group, treatemet of patients with myelodysplastic syndromes (MDS) with 10-30% bone marrow blasts and hematopoietic failure is analyzed. (en)
Title
  • Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia
  • Léčba pomocí nízkých dávek cytosinu arabinoside (LD-AraC) vs LD-AraC plus granulocytů / makrofágů vs LD-AraC plus interleukinu-3 u MDS u pacientů s vysokým rizikem vývoje akutní leukémie. (cs)
  • Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia (en)
skos:prefLabel
  • Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia
  • Léčba pomocí nízkých dávek cytosinu arabinoside (LD-AraC) vs LD-AraC plus granulocytů / makrofágů vs LD-AraC plus interleukinu-3 u MDS u pacientů s vysokým rizikem vývoje akutní leukémie. (cs)
  • Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia (en)
skos:notation
  • RIV/00023736:_____/05:00007603!RIV09-MZ0-00023736
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • V
http://linked.open...iv/cisloPeriodika
  • 11
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 528475
http://linked.open...ai/riv/idVysledku
  • RIV/00023736:_____/05:00007603
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • EORTC Leukemia Cooperative Group; MDS (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV
  • [490D8C46CBEB]
http://linked.open...i/riv/nazevZdroje
  • Leukemia
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 19
http://linked.open...iv/tvurceVysledku
  • Neuwirtová, R.
  • Čermák, Jaroslav
  • Fenaux, P.
  • Amadori, S.
  • Suciu, S.
  • Zwierzina, H.
  • De Witte, T. M.
  • Willemze, R.
  • Beksac, M.
  • Harousseau, J.
  • Loeffler-Ragg, J.
  • Nuessler, V.
  • Solbu, G.
http://linked.open...ain/vavai/riv/wos
  • 000232833100010
issn
  • 0887-6924
number of pages
is http://linked.open...avai/riv/vysledek of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 85 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software